Phase i safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy

Melanoma Research

Volumn 20, Issue 6, 2010, Pages 501-506

  Hwu, Wen Jen ^a   Knight, Robert D ^c   Patnana, Madhavi ^b   Bassett, Roland ^a   Papadopoulos, Nicholas E ^a   Kim, Kevin B ^a   Hwu, Patrick ^a   Bedikian, Agop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Diagnostic Imaging ^*  (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

chemotherapy; dacarbazine; immunomodulatory therapy; lenalidomide; melanoma; metastatic melanoma

Indexed keywords

ANTIDEPRESSANT AGENT; DACARBAZINE; LENALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN ISCHEMIA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOMODULATION; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VAGINA BLEEDING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; THALIDOMIDE;

EID: 78349307945     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32833faf18     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 American Joint Committee on Cancer (AJCC) melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
3. Tsao H, Atkins MB, Sober AJ. Medical progress: management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012.
4. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968-975.
5. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748-5754.
6. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19:21-34.
7. Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 2002; 20:2610-2615.
8. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. Randomized phase II study of temozolomide given every 8 h or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003; 21:2551-2557.
9. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21:3351-3356.
10. Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, et al. Phase II study of temozolomide plus pegylated interferon-alfa-2b for metastatic melanoma. Cancer2006; 106:2445-2451.
11. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and Tcell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999; 163:380-386.
12. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216.
13. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004; 90:955-961.
14. Shama RA, Steward WP, Daines CA, Knight RD, O'Byrne KJ, Dalgleish AG. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer2006; 42:2318-2325.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
16. Clark IJ, Moon J, Hunchins LF, Sosman JA, Kast M, Da Silva DM, et al. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 2010; 116:424-431.
17. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87:1166-1172.
18. Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, et al. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer2010; 116:146-154.
19. Glaspy J, Atkin MB, Richards JM, Agarwala SS, O'Day S, Knight RD, et al. Results of a multicenter, randomized double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer2009; 115:5228-5236.
20. Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH,Thatcher N, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002; 12:175-178.
21. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer2005; 103:2590-2597.